RecruitingPhase 1NCT07653503
Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)
Sponsor
University Medical Center Groningen
Enrollment
12 participants
Start Date
Jan 5, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
We aim to determine feasibility, safety and efficacy of TDLN-targeted immune checkpoint inhibition in different doses (nivolumab) in patients with cervical cancer.
Eligibility
Sex: FEMALEMin Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Nivolumab for people with cervical carcinoma. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNivolumab
Subcutaneous injection of nivolumab
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07653503
Related Trials
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
NCT0728143018 locations
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
NCT072850441 location
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
NCT0558112137 locations
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
NCT069679611 location
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
NCT045677713 locations